Diffuse Large B-Cell Lymphoma Industry Share and Size, Trends and Growth, Analysis and Pipeline Review, H2 2015 Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2015', provides an overview of the Diffuse Large B-Cell Lymphoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Diffuse Large B-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diffuse Large B-Cell Lymphoma and special features on late-stage and discontinued projects. Source Link: http://www.radiantinsights.com/research/diffuse-large-b-cell-lymphoma-pipelinereview-h2-2015 Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Diffuse Large B-Cell Lymphoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diffuse Large B-Cell Lymphoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diffuse Large B-Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Diffuse Large B-Cell Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diffuse Large B-Cell Lymphoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diffuse Large B-Cell Lymphoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Buy a Sample copy of This Report: http://www.radiantinsights.com/checkout/145819 Table of Contents Table of Contents 2 List of Tables 7 List of Figures 9 Introduction 11 Global Markets Direct Report Coverage 11 Diffuse Large B-Cell Lymphoma Overview 12 Therapeutics Development 13 Pipeline Products for Diffuse Large B-Cell Lymphoma - Overview 13 Pipeline Products for Diffuse Large B-Cell Lymphoma - Comparative Analysis 14 Diffuse Large B-Cell Lymphoma - Therapeutics under Development by Companies 15 Diffuse Large B-Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes 22 Diffuse Large B-Cell Lymphoma - Pipeline Products Glance 23 Late Stage Products 23 Clinical Stage Products 24 Early Stage Products 25 Source Link: http://www.radiantinsights.com/research/diffuse-large-b-cell-lymphoma-pipelinereview-h2-2015 About Us: Radiant Insights Inc. is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions. Contact Details: Michelle Thoras Corporate Sales Specialist, USA Radiant Insights, Inc 28 2nd Street, Suite 3036 San Francisco, CA 94105 United States Phone: 1-415-349-0054 Toll Free: 1-888-202-9519 Website: http://www.radiantinsights.com/ Email: [email protected]
© Copyright 2024